Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Auditor change
Employment agrmnt
Quarterly results
Appointed director
CC transcript
|
|
YIELD10 BIOSCIENCE, INC. (YTEN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/02/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/18/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/12/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/07/2023 |
DEL AM
| Form DEL AM - Delaying amendment: |
| 06/30/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/26/2023 |
SC 13D/A
| SCHULER JACK W reports a 21.7% stake in Yield10 Bioscience, Inc. |
| 05/19/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT YIELD10 BIOSCIENCE, INC. Warrant Shares: [ · ] Issue Date and Initial Exercise Date: [ · ], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from YIELD10 BIOSCIENCE, INC., a Delaware corporation , up to [ · ] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and ...",
"FORM OF COMMON STOCK PURCHASE WARRANT YIELD10 BIOSCIENCE, INC. Warrant Shares: [ · ] Issue Date: [ · ], 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the Issue Date and on or prior to 5:00 p.m. on the fifth anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from YIELD10 BIOSCIENCE, INC., a Delaware corporation , up to [ · ] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitali...",
"Yield10 Bioscience, Inc. 19 Presidential Way Woburn, Massachusetts 01801",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of May 3, 2023 between Yield10 Bioscience, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and the Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Private Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW,...",
"Yield10 Bioscience Announces Pricing of $3.0 Million Registered Direct Offering and Concurrent Private Placement" |
|
| 05/03/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/05/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/11/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/09/2022 |
8-K
| Quarterly results |
|
|
|